Xencor, Inc. (XNCR)

NASDAQ: XNCR · IEX Real-Time Price · USD
22.12
-0.31 (-1.36%)
Mar 28, 2024, 3:56 PM EDT - Market open

Company Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.

The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.

The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors.

In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus.

The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression.

It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor, Inc.
Xencor logo
Country United States
Founded 1997
IPO Date Dec 3, 2013
Industry Biotechnology
Sector Healthcare
Employees 280
CEO Dr. Bassil I. Dahiyat Ph.D.

Contact Details

Address:
465 N. Halstead St., Suite 200
Pasadena, California 91107
United States
Phone 626-305-5900
Website xencor.com

Stock Details

Ticker Symbol XNCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326732
CUSIP Number 98401F105
ISIN Number US98401F1057
Employer ID 20-1622502
SIC Code 2834

Key Executives

Name Position
Dr. Bassil I. Dahiyat Ph.D. Co-Founder, Chief Executive Officer, President and Director
John J. Kuch Senior Vice President and Chief Financial Officer
Dr. John R. Desjarlais Ph.D. Executive Vice President of Research and Chief Scientific Officer
Celia E. Eckert J.D. Senior Vice President, General Counsel and Corporate Secretary
Dr. Nancy Valente M.D. Executive Vice President and Chief Development Officer
Charles Liles Associate Director and Head of Corporate Communications and Investor Relations
Jennifer Sandoz Vice President of Human Resources
Dr. Jeremy Grunstein Ph.D. Senior Vice President of Business Development
Kirk Rosemark RAC Senior Vice President of Regulatory Affairs and Quality Assurance
Eric P. Kowack Senior Vice President of Program Leadership and Alliance Management

Latest SEC Filings

Date Type Title
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 6, 2024 144 Filing
Mar 6, 2024 8-K Current Report
Mar 5, 2024 144 Filing
Mar 5, 2024 144 Filing
Mar 5, 2024 144 Filing
Mar 5, 2024 144 Filing